ASTELLAS PHARMA

🇯🇵Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/
Clinical Trials
Related News

Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study

Phase 3
Completed
Conditions
Lupus Nephritis
First Posted Date
2007-01-31
Last Posted Date
2007-01-31
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
64
Registration Number
NCT00429377

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis

First Posted Date
2007-01-18
Last Posted Date
2015-09-02
Lead Sponsor
Astellas Pharma Inc
Registration Number
NCT00423163

Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward

Phase 4
Terminated
Conditions
Schizophrenia
Interventions
Drug: Zotepine
Drug: Risperidone
First Posted Date
2007-01-05
Last Posted Date
2010-04-16
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
39
Registration Number
NCT00418873

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

First Posted Date
2006-12-19
Last Posted Date
2024-12-10
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
527
Registration Number
NCT00412893
Locations
🇦🇷

Hospital Italiano de Buenos Aires, Ciudad Autonoma, Argentina

🇺🇸

University of Alabama, Birmingham, Alabama, United States

🇺🇸

University of Chicago, Division of Infectious Diseases, Chicago, Illinois, United States

and more 78 locations

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

First Posted Date
2006-12-19
Last Posted Date
2024-12-10
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
450
Registration Number
NCT00413218
Locations
🇺🇸

Idaho Falls Infectious Diseases PLLC, Idaho Falls, Idaho, United States

🇺🇸

Somero Research Corporation, Palm Desert, California, United States

🇺🇸

Loyola University Hospital, Maywood, Illinois, United States

and more 110 locations

Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: ASK8007
Drug: Placebo
First Posted Date
2006-12-14
Last Posted Date
2013-03-21
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
54
Registration Number
NCT00411424

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

First Posted Date
2006-12-13
Last Posted Date
2014-04-04
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
200
Registration Number
NCT00410514

Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement

Phase 2
Completed
Conditions
Thromboembolism
Interventions
Drug: YM150
Drug: enoxaparin
First Posted Date
2006-12-06
Last Posted Date
2011-12-19
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
367
Registration Number
NCT00408239

Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque

First Posted Date
2006-12-06
Last Posted Date
2011-11-17
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
50
Registration Number
NCT00408382

A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients

Phase 3
Completed
Conditions
Transplantation
Interventions
Drug: Tacrolimus
First Posted Date
2006-10-05
Last Posted Date
2014-07-09
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
112
Registration Number
NCT00384202
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy